ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The efficacy and safety of tacrolimus and entecavir combination therapy in the treatment of hepatitis B virus-associated glomerulonephritis: a multi-center, placebo controlled, and single-blind randomized trial

Xie, Xin-Fu; Xie, Bing-Ying; Zhang, Wen-Hao; Hou, Ji-Hua; Liu, Ding-Lin; Zhang, Li; Xu, Li-Xia; Li, Zhi-Lian; Li, Rui-Zhao; Ye, Zhi-Ming*广东省人民医院; 南方医科大学; 汕头大学
Annals of Palliative Medicine2022-5DOI: 10.21037/apm-22-328
13阅读
引用收藏
分享

摘要

Background: The proteinuria remission in hepatitis B virus-associated glomerulonephritis (HBV-GN) patients with massive proteinuria treated with antiviral therapy was low. Tacrolimus (TAC) is effective in primary nephropathy and can inhibit HBV infection by inhibiting HBV binding to sodium taurocholate cotransporting polypeptidc on liver cells. This study evaluated the efficacy and safety of TAC combined with ETV compared with entecavir (ETV) monotherapy in HBV-GN. @@@ Methods: Patients diagnosed with HBV-GN were recruited for this prospective, randomized, controlled, multicenter, single-blinded study in China. Patients were given TAC and ETV therapy (the TAC+ETV group) or placebo and ETV therapy (the ETV group) for 26 weeks. The efficacy endpoints included proteinuria remission, including complete and partial remission (CR and PR), the change of 24-hour proteinuria (24 h UP) and HBV DNA titer. The safety endpoints were the incidence of HBV virologic breakthrough and adverse events. @@@ Results: There were 14 patients in the TAC+ETV group and 17 patients in the ETV group. In the intention-to-treat analyses, 64.3% (9/14) of patients in the TAC+ETV group and 58.8% (10/17) in the ETV group achieved PR or CR at 26 weeks (P=0.38). At week 14, 42.9% (6/14) and 41.2% (7/17) of patients in the TAC+ETV group and the ETV group, respectively, achieved PR or CR (P=0.23). At week 26, the 24 h UP had decreased by 2.63 +/- 6.33 g from baseline in the TAC+ETV group and 1.42 +/- 4.34 g in the ETV group (P=0.55). The serum albumin increased by 11.1 +/- 7.30 g/L from baseline in the TAC+ETV group and 3.81 +/- 5.09 g/L in the ETV group (P4/001). Log10 HBV DNA decreased by 1.49 +/- 2.04 from baseline in the TAC+ETV group and 2.47 +/- 2.08 in the ETV group (P=0.37); 28.6% (4/14) patients had HBV DNA virologic breakthrough in the ETV group, while none in the TAC+ETV group (P=0.29). @@@ Conclusions: In adult HBV-GN patients, TAC and ETV combination therapy may significantly improve serum albumin levels without increasing the risk of HBV reactivation compared with entecavir monotherapy.

学科与关键词

关键词
Hepatitis B virus-associated nephropathy (HBV-GN)tacrolimus (TAC)entecavirproteinuria
相关
加载中…
  • 乙型肝炎病毒相关性肾炎诊治进展
    庞浩文中国药物经济学, 2019, (11): 126-128.
  • Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial
    Chen Wei; Tang Xueqing; Liu Qinghua; Chen Weiying; Fu Ping; Liu Fang; Liao Yunhua; Yang Zhenhua; Zhang Jinli; Chen Jian; Lou Tanqi; Fu Junzhou; Kong Yaozhong; Liu Zhengrong; Fan An; Rao Shaoqi; Li Zhibin; Yu Xueqing*AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57(2): 235-244.被引 49
  • Viral-Associated GN: Hepatitis B and Other Viral Infections.
    Kupin, Warren L*Clin J Am Soc Nephrol, 2017, 12(9): 1529-1533.
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Palliative Medicine
发表日期
2022-05
卷期
第 11 卷, 第 5 期
页码
1762-1773
DOI
10.21037/apm-22-328
期刊等级
4区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [2020A1515010137]; Scientific Research Project of Guangdong Provincial People's Hospital Summit Plan [KJ012019436, DFJH201911]; Guangzhou Scientific Research Project [201707010321]

作者

  • X

    Xie, Xin-Fu (第一作者)

    guangdong prov peoples hosp · 2 · southern med univ

  • X

    Xie, Bing-Ying

    guangdong prov peoples hosp · shantou univ

查看全部 10 位作者收起作者
  • Z

    Zhang, Wen-Hao

    guangdong prov peoples hosp · shantou univ

  • H

    Hou, Ji-Hua

    guangdong prov peoples hosp · 2 · southern med univ

  • L

    Liu, Ding-Lin

    guangdong prov peoples hosp

  • Z

    Zhang, Li

  • X

    Xu, Li-Xia

    guangdong prov peoples hosp

  • L

    Li, Zhi-Lian

  • L

    Li, Rui-Zhao

    guangdong prov peoples hosp

  • Y

    Ye, Zhi-Ming (通讯)

    guangdong prov peoples hosp · 2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417